Key Highlights

  • USD 22.7 million was the preliminary third quarter revenue announced by MDxHealth (NASDAQ:MDXH) on October 15, 2026, flat on the prior year and 7.5% below the published consensus of USD 24.55 million, own arithmetic on two published numbers.
  • 40% is the decline per published market data (October 16, 2026 premarket): USD 0.3601 against the October 15 close of USD 0.6036, own arithmetic. Relative volume was 3.73, and MDxHealth (NASDAQ:MDXH) suspended its full-year revenue guidance of USD 110 million to USD 115 million.
  • USD 31.7 million was cash at September 30, 2026, versus USD 19.2 million at June 30 before a USD 20 million registered direct placement on August 11. Non-current borrowings were USD 96.4 million at June 30, 2026, and total equity was negative USD 30.4 million.
  • Hold is the new rating from Lake Street, which cut its target to USD 0.50 from USD 3, and from Craig-Hallum, both on October 16, 2026. MDxHealth (NASDAQ:MDXH) received a Nasdaq minimum bid notice on July 2, 2026.

Price Action and Catalyst Review

The catalyst is the company release of October 15, 2026. MDxHealth (NASDAQ:MDXH) stated preliminary, unaudited third quarter revenue from continuing operations of USD 22.7 million, equal to USD 22.7 million a year earlier after re-presenting figures without the discontinued Resolve mdx business. Published market data show 975,570 shares traded in the premarket against an implied average of 261,500 (own arithmetic from relative volume of 3.73). Turnover was USD 351,000 (price times volume, own arithmetic), or 1.0% of the USD 34.36 million market capitalization.

Test Volumes and Sales Force Attrition

A diagnostics company earns revenue when physicians order tests, so lost sales representatives cut volume until territories are refilled. Tissue-based Confirm mdx and GPS mdx volume was 11,232 in the quarter, down 11% year over year. Liquid-based Exo mdx volume was 11,792 against 4,600 a year earlier, a 2.6-fold rise (own arithmetic). The chief executive officer attributed the shortfall to unexpected sales force turnover and said it disrupted forecasting, hence withdrawal rather than a reduction.

Debt, Covenants and Listing Compliance

Per the preliminary release, non-current loans were USD 96.4 million at June 30, 2026, up from USD 76.2 million at year end, and compliance with financial covenants is listed as a risk. Cash of USD 31.7 million at September 30 compares with USD 39.2 million had the placement been added to June 30 cash, an implied USD 7.5 million decline before fees (own arithmetic). The July 2 Nasdaq notice carries a 180-day cure period ending December 29, 2026 (own arithmetic); failure to regain a USD 1.00 closing bid exposes the shares to delisting proceedings. A reverse split or equity sale is not announced.

Where Things Stand

MDxHealth (NASDAQ:MDXH) fell 40% because a revenue miss, flat year-over-year sales and withdrawn guidance removed the earnings path that supported the valuation, and two analyst firms moved to Hold. The balance of evidence is mixed: liquid test volume rose 2.6-fold and cash stands at USD 31.7 million, yet tissue volume fell 11%, borrowings are USD 96.4 million and equity is negative. No new offering was identified in filings dated October 15 or 16, 2026. The next dated catalysts are the November 12, 2026 call, the December 29, 2026 Nasdaq cure deadline and evidence that sales force attrition has stopped.